Compare iShares 3 7 Year Treasury Bond ETF (IEI) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 3 7 Year Treasury Bond ETF vs Sana Biotechnology Inc — how do they compare? iShares 3 7 Year Treasury Bond ETF trades at $116.37, while Sana Biotechnology Inc trades at $3.13 (market cap $879.40M). The key difference: Sana Biotechnology Inc is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IEI | SANA | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $120.72 | $5.92 |
52-Week Low | $116.45 | $2.68 |
Market Cap | — | $879.40M |
Enterprise Value | — | $853.59M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEI (iShares 3-7 Year Treasury Bond ETF) trades at $116.76, down 0.19% with a bearish technical signal from moving averages. The ETF focuses on intermediate-term U.S. Treasury bonds, offering lower volatility compared to corporate bond alternatives. Recent news highlights institutional selling by AlTi Global Inc. and competitive pressure from Vanguard's lower-cost bond ETFs.
The outlook remains cautious amid Federal Reserve uncertainty and rising inflation concerns. While Treasury ETFs provide safety during market stress, IEI faces headwinds from potential rate hikes and stronger-yielding alternatives. Key risks include interest rate sensitivity and investor preference for higher-yield bond options in the current environment.
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
